Skip to content

UroGen Pharma URGN Finance Lease Liability, Current

Finance Lease Liability, Current at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$52K

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.73B+71.7%
Enterprise value$1.81B+80.9%
P/S12.3×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's finance lease liability, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's finance lease liability, current?
UroGen Pharma (URGN) reported finance lease liability, current of $1.33M in Q1 2026.
How has UroGen Pharma's finance lease liability, current changed year-over-year?
UroGen Pharma's finance lease liability, current increased by 70.1% year-over-year, from $780K to $1.33M.
What does finance lease liability, current mean?
Finance lease liabilities (current) represent the portion of lease obligations that are due to be paid within the next twelve months. These obligations arise from long-term contracts where the company effectively controls the leased asset. This metric is critical for assessing near-term liquidity and cash flow requirements.